Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical antifungal (morpholine)

Amorolfine

Brand names: Loceryl, Curanail

Amorolfine is a topical antifungal, most commonly used as a nail lacquer, for mild fungal nail infections (onychomycosis) and some skin dermatophyte infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a morpholine antifungal that inhibits fungal sterol biosynthesis, disrupting the fungal cell membrane to produce fungistatic and fungicidal effects.

Prescribing in practice

  • It is suitable only for mild distal nail infection not involving the nail matrix; more extensive or matrix involvement usually requires systemic antifungal therapy.
  • The affected nail should be filed and cleaned before each application of the lacquer, and treatment continued for the prolonged course needed for nail regrowth.
  • Avoid contact with the eyes, ears and mucous membranes.

Monitoring

Monitoring is clinical, reviewing nail or skin response over the extended treatment period.

Counselling the patient

  • File and clean the nail before applying the lacquer as directed.
  • Treatment must continue for many months until healthy nail has fully grown out.
  • Avoid cosmetic nail varnish over the treated nail unless advised it is compatible.

Evidence & guidelines

Amorolfine nail lacquer is an established topical option for mild, non-matrix fungal nail infection in current prescribing references.

Reference: SmPC Loceryl / Curanail; BAD Onychomycosis Guideline 2014; NICE CKS Fungal Nail Infections; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways